List of Horizant drug patents

Horizant is owned by Azurity.

Horizant contains Gabapentin Enacarbil.

Horizant has a total of 6 drug patents out of which 1 drug patent has expired.

Expired drug patents of Horizant are:

  • US8048917

Horizant was authorised for market use on 06 April, 2011.

Horizant is available in tablet, extended release;oral dosage forms.

Horizant can be used as treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults, management of postherpetic neuralgia (phn) in adults, treatment of moderate-to-severe primary restless leg syndrome in adults.

The generics of Horizant are possible to be released after 10 June, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8048917 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Nov, 2022

(2 months ago)

US6818787 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(2 years from now)

US8026279 AZURITY Crystalline form of γ-aminobutyric acid analog
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034 AZURITY Crystalline form of γ-aminobutyric acid analog
Jan, 2025

(1 year, 11 months from now)

US8114909 AZURITY Treating or preventing restless legs syndrome using prodrugs of GABA analogs
Apr, 2026

(3 years from now)

US8795725 AZURITY GABA analog prodrug sustained release oral dosage forms
Jun, 2029

(6 years from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Market Authorisation Date: 06 April, 2011

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; Management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HORIZANT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in